{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:11:32Z","timestamp":1790125892522,"version":"4.0.1"},"reference-count":133,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the role of small\u2010molecule calcitonin gene\u2013related peptide receptor antagonists (gepants) in the acute treatment of migraine, particularly in relation to triptan treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Triptans have established efficacy and are widely prescribed for the acute treatment of migraine. However, triptans may not be recommended for some individuals due to cardiovascular contraindications and precautions, as well as other comorbidities, and many may discontinue triptans because of inadequate or inconsistent symptom relief or poor tolerability. Several gepants are also indicated for the treatment of migraine (both acute and preventive), and their demonstrated efficacy and safety may address some challenges associated with triptans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This narrative review addresses considerations for the acute treatment of migraine through summarizing literature and data from preclinical studies and clinical trials of triptans and gepants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We consider triptans and gepants, where available, first\u2010line treatment options for the acute treatment of migraine. Triptans may be prescribed in the absence of contraindications, significant risk of cardiovascular disease, or risk for or history of medication\u2010overuse headache. In those who have contraindications or precautions for triptans, those who do not have an adequate response to triptans, and those unable to tolerate them, gepants are often an appropriate option. The efficacy and safety of gepants for the acute treatment of migraine has been established through clinical trials and open\u2010label extension studies and based on real\u2010world evidence. Gepants have demonstrated efficacy and tolerability in triptan insufficient responders, perhaps because of their distinct mechanisms of action. Additionally, the safety of gepants, including relative cardiovascular safety, is supported in pivotal controlled trials and open\u2010label extension trials. In experimental settings and through their use as preventive treatment for migraine, gepants appear unlikely to produce medication\u2010overuse headache. In addition, one gepant (ubrogepant) has demonstrated efficacy in preventing headache onset when given during the prodrome, a finding that has not been demonstrated for triptans. A single\u2010arm, open\u2010label study of naratriptan given during the prodrome suggested fewer subsequent headaches, but interpretation is limited because there was no contemporaneous control group. Limited head\u2010to\u2010head clinical trials comparing gepants and triptans have not demonstrated significant differences. Prescribers of both triptans and gepants should be mindful of potential drug\u2013drug interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Key advantages of gepants include their favorable tolerability, efficacy for the acute treatment of both the prodromal\/premonitory phase (ubrogepant) and the headache phase of migraine (ubrogepant, rimegepant, zavegepant), lack of cardiovascular contraindications, and lack of association with medication\u2010overuse headache. Disadvantages include limitations due to cost and access and CYP3A4 drug interactions for most gepants. Together, the advantages may help to optimize patient care and lead to better persistence and effectiveness in a real\u2010world setting. Head\u2010to\u2010head studies are needed to clarify the comparative effectiveness of triptans and gepants.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.70047","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:58:36Z","timestamp":1771480716000},"page":"976-989","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrating gepants into clinical practice for the acute treatment of migraine"],"prefix":"10.1111","volume":"66","author":[{"given":"Richard B.","family":"Lipton","sequence":"first","affiliation":[{"name":"The Saul R. Korey Department of Neurology, and The Montefiore Headache Center Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9486-6790","authenticated-orcid":false,"given":"David W.","family":"Dodick","sequence":"additional","affiliation":[{"name":"Mayo Clinic  Phoenix Arizona USA"},{"name":"Atria Research and Global Health Institute  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Davis","sequence":"additional","affiliation":[{"name":"Kolvita Family Medical Group  Mission Viejo California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Nahas","sequence":"additional","affiliation":[{"name":"Department of Neurology Thomas Jefferson University  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[{"name":"Division of Biomedical Sciences King Abdullah University of Science and Technology  Thuwal Saudi Arabia"},{"name":"National Institute for Health and Care Research, King's Clinical Research Facility and Wolfson Sensory, Pain, and Regeneration Centre  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0592-1"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00328-4"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098617690485"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.181424"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1909"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199701000-00003"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-020-00179-3"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2000.00030.x"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.01.005"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410370873"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-0615-6"},{"key":"e_1_2_11_14_1","volume-title":"REYVOW [package insert]","year":"2020"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2732"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419855080"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006641"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz134"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00059.2021"},{"key":"e_1_2_11_20_1","volume-title":"Ubrelvy [package insert]","year":"2025"},{"key":"e_1_2_11_21_1","volume-title":"Nurtec ODT [package insert]","year":"2025"},{"key":"e_1_2_11_22_1","volume-title":"Qulipta [package insert]","year":"2025"},{"key":"e_1_2_11_23_1","volume-title":"Zavzpret [package insert]","year":"2025"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01264-5"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000806"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080107"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2015"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S132833"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0811-5"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16711"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00234-7"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.166"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13766"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01683-5"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00126-6"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S453806"},{"issue":"1","key":"e_1_2_11_40_1","first-page":"140","article-title":"Rimegepant 75 mg, an oral calcitonin gene\u2010related peptide antagonist, for the acute treatment of migraine: two phase 3, double\u2010blind, randomized, placebo\u2010controlled trials [abstract MTIS2018\u2010171]","volume":"38","author":"Lipton RB","year":"2018","journal-title":"Cephalalgia"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413500727"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14994"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01577"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231219505"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251395298"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251343309"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S453937"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01378-5"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S456006"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00517-8"},{"key":"e_1_2_11_51_1","article-title":"Rapid response, January 10, 2025: Re: Karlsson WK, Ostinelli EG, Zhuang ZA, et\u00a0al. comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta\u2010analysis","volume":"386","author":"Lipton RB","year":"2024","journal-title":"BMJ"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00868340"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1996.00550110072014"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1997.1706647.x"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.5.1210"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3810737.x"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3804281.x"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3810748.x"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1999.019005525.x"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1159\/000008094"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2000.00004.x"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.1.156"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2000.00069.x"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1159\/000047960"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2002.02009.x"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.8.1210"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2002.00300.x"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2003.00554.x"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2003.03044.x"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2003.03043.x"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00783.x"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1159\/000079544"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.05178.x"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.01053.x"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61626-8"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410388435"},{"key":"e_1_2_11_77_1","volume-title":"Migraine: Developing Drugs for Acute Treatment. Guidance for Industry","author":"Food and Drug Administration","year":"2018"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.pn.2025.03.3.3"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2001.00169.x"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/17581869.2025.2494494"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2006.01194.x"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01913-0"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414550416"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1177\/1941874412439583"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2022.100420"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12962"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1177\/2150132720963680"},{"issue":"1","key":"e_1_2_11_88_1","article-title":"Characterization of the effects of the calcitonin gene\u2013related peptide (CGRP) receptor antagonists, atogepant and ubrogepant, on isolated human coronary, cerebral, and middle meningeal arteries [abstract OR13]","volume":"59","author":"Edvinsson L","year":"2019","journal-title":"Headache"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfac051"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2025.149946"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.2001.81.1.299"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21897"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00683.x"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2009.01873.x"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418804157"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420920006"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420938652"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa211"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14439"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779543"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4853"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.15004"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.171101"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25831"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213852"},{"key":"e_1_2_11_107_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1399792"},{"key":"e_1_2_11_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-024-00626-1"},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1431562"},{"key":"e_1_2_11_110_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-025-00757-z"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01904-1"},{"key":"e_1_2_11_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.04.2172"},{"key":"e_1_2_11_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.15027"},{"key":"e_1_2_11_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13682"},{"key":"e_1_2_11_115_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241232944"},{"key":"e_1_2_11_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14854"},{"key":"e_1_2_11_117_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01110-9"},{"key":"e_1_2_11_118_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905307"},{"key":"e_1_2_11_119_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02748.x"},{"key":"e_1_2_11_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(00)00010-1"},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.261065"},{"key":"e_1_2_11_122_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14089"},{"issue":"1","key":"e_1_2_11_123_1","article-title":"Rimegepant for the acute treatment of migraine: subgroup analyses from 3 phase 3 clinical trials by number of triptans previously tried and failed [abstract PO268]","volume":"41","author":"Jensen CM","year":"2021","journal-title":"Cephalalgia"},{"key":"e_1_2_11_124_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411433042"},{"key":"e_1_2_11_125_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201031"},{"key":"e_1_2_11_126_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03679-7"},{"key":"e_1_2_11_127_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-015-0160-2"},{"key":"e_1_2_11_128_1","volume-title":"Tosymra [package insert]","year":"2023"},{"key":"e_1_2_11_129_1","volume-title":"Imitrex [package Insert]","year":"2024"},{"key":"e_1_2_11_130_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061656"},{"key":"e_1_2_11_131_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14095"},{"key":"e_1_2_11_132_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14433"},{"key":"e_1_2_11_133_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14871"},{"key":"e_1_2_11_134_1","first-page":"313","volume-title":"Proceedings of the 67th Annual Scientific Meeting of the American Headache Society (AHS)","author":"Nahas SJ","year":"2025"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.70047","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.70047","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.70047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T07:24:40Z","timestamp":1775114680000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.70047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":133,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/head.70047"],"URL":"https:\/\/doi.org\/10.1111\/head.70047","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"2025-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}